Bernadette Connaughton

Director

Bernadette Connaughton (Director) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Halozyme Therapeutics, Inc. (HALO). The largest single filing was $167K of HALO (1,626 sh × $102.80, as filed), executed Aug 10.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 6 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$768K

shares × price, as filed

Last traded

Aug 10

Filed Aug 11

Median ADV $214.5M across their filed names

Open performance→

Volume by month

Buys $0 Sells $987K

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 6 filings

Sector per market data · by filing · past 12 months

Most traded names

HALO

Halozyme Therapeutics, Inc. HALO · 0 buys · 7 sells 7 filings

Recent filings

HALOSALE Halozyme Therapeutics, Inc. View filing → $167K
1,626 sh × $102.80
Exec Aug 10
Filed Aug 11 · 5:43 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $108K
1,625 sh × $66.21
Exec Jun 1
Filed Jun 2 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $103K
1,625 sh × $63.48
Exec May 1
Filed May 5 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $140K
2,000 sh × $70.25
Exec Jan 5
Filed Jan 6 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $137K
2,000 sh × $68.48
Exec Nov 10 2025
Filed Nov 12 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $113K
1,500 sh × $75.09
Exec Oct 1 2025
Filed Oct 1 2025 · 5:30 PM ET HALOSALE Halozyme Therapeutics, Inc. View filing → $219K
2,977 sh × $73.62
Exec Sep 2 2025
Filed Sep 2 2025 · 5:30 PM ET